GO:0042169 SH2 domain binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042169 (SH2 domain binding) describes the molecular function of binding to an SH2 domain, a ~100-residue alpha+beta protein module that recognizes phosphorylated tyrosine motifs.
• SH2 domain binding is typically mediated by short phosphotyrosine-containing peptides, and the selectivity of these interactions is a central determinant of signaling specificity.
• Dysregulated SH2 domain binding underlies many cancers and immune disorders, making these interactions attractive drug targets.
• SH2 domains can also bind lipids, expanding their functional repertoire beyond phosphopeptide recognition.
• Key experimental approaches include in-solution binding assays, proximity ligation, histochemistry, and high-throughput mapping such as SH2scan.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of SH2 domain binding in disease and development.
Description
SH2 domain binding (GO:0042169) is a molecular function that refers to the binding of a protein or ligand to an SH2 (Src homology 2) domain, a compact protein module of about 100 amino acids belonging to the alpha+beta domain class. This function is fundamental to intracellular signal transduction because SH2 domains recognize phosphorylated tyrosine residues within specific sequence contexts, thereby coupling activated tyrosine kinases to downstream effectors. The human genome encodes more than a hundred SH2 domains, and their binding preferences dictate the wiring of signaling networks that control cell growth, differentiation, and immune responses. Because SH2 domain binding is so central to signaling, its dysregulation is implicated in cancer, autoimmunity, and other diseases, and it has become a major focus for targeted drug discovery. Researchers study SH2 domain binding to understand how specificity is achieved, how it can be modulated, and how it contributes to disease, using a growing toolkit of biochemical, structural, and CRISPR-based methods.
SH2 domain binding At A Glance
| GO ID | GO:0042169 |
|---|---|
| GO term | SH2 domain binding |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Binding to an SH2 domain, typically via phosphotyrosine motifs, to mediate protein-protein interactions in signaling |
| Domain class | Alpha + beta domain class, ~100 amino acids |
| Common ligands | Phosphotyrosine-containing peptides and, in some cases, lipids |
| Disease relevance | Cancer, immune disorders, and other signaling-related diseases |
| Research methods | In-solution binding assays, proximity ligation, histochemistry, SH2scan |
What Is GO:0042169?
According to the Gene Ontology, GO:0042169 (SH2 domain binding) is defined as binding to an SH2 domain (Src homology 2) of a protein, a protein domain of about 100 amino-acid residues and belonging to the alpha + beta domain class. In practice, this means the function is carried out by a protein or peptide that physically interacts with an SH2 domain, often through a phosphotyrosine-containing motif, but also potentially through other interfaces or lipids.
Why Is SH2 domain binding Important in Cell Biology?
SH2 domain binding is important because it is a primary mechanism by which cells convert tyrosine phosphorylation signals into specific biological outcomes. The selectivity of SH2 domain-ligand interactions determines which downstream pathways are activated, and perturbations in this code can lead to diseases such as cancer and immunodeficiency. Moreover, because SH2 domains are modular and druggable, they represent attractive targets for therapeutic intervention, and understanding their binding properties is essential for rational drug design.
• SH2 domain binding is a key node in tyrosine kinase signaling, affecting cell proliferation, survival, and differentiation.
• Altered SH2 domain binding can drive oncogenesis by rewiring signaling networks.
• SH2 domains are found in many human proteins, and their binding specificities are critical for signaling fidelity.
• Some SH2 domains also bind lipids, adding another layer of regulation.
• SH2 domain binding is a target for small-molecule inhibitors and degraders.
• Methods to study SH2 domain binding are well established, including in-solution assays and histochemistry.
• Tensin, a focal adhesion protein, contains an SH2 domain and is involved in cell migration and cancer.
• SH2 domain binding is relevant to immune receptor signaling and autoimmune diseases.
• High-throughput mapping of SH2 domain binding selectivity accelerates drug discovery.
• CRISPR models allow functional validation of SH2 domain binding in disease contexts.
Molecular Mechanism of SH2 domain binding
Phosphotyrosine recognition
In simple terms: SH2 domains act like molecular switches that turn on when they bind to a phosphorylated tyrosine on another protein.
The canonical mechanism of SH2 domain binding involves the recognition of a phosphotyrosine residue within a specific peptide sequence. The SH2 domain contains a conserved pocket that accommodates the phosphotyrosine, and additional surface residues determine specificity for the residues immediately C-terminal to the phosphotyrosine. This binding is typically of moderate affinity but high specificity, allowing SH2 domains to discriminate among thousands of potential partners.
Specificity and the FLVR motif
In simple terms: A small region in the SH2 domain, called the FLVR motif, helps decide which phosphorylated partners it will bind.
The FLVR motif (named after conserved residues) is a key structural element that shapes the phosphotyrosine-binding pocket and influences ligand selectivity. Variations in this motif and surrounding loops contribute to the diverse binding preferences observed across the SH2 domain family. This diversity allows different SH2 domains to participate in distinct signaling pathways despite sharing a common fold.
Lipid binding by SH2 domains
In simple terms: Some SH2 domains can also stick to lipids, not just phosphorylated proteins.
Beyond phosphopeptides, certain SH2 domains have been shown to bind lipids, which can modulate their localization and function. Lipid binding may occur through a distinct surface or overlap with the phosphotyrosine-binding site, and it can influence signaling outcomes. This expands the functional repertoire of SH2 domains beyond protein-protein interactions.
Regulation by phosphorylation and competition
In simple terms: Whether an SH2 domain binds depends on the phosphorylation state of its partners and on competition with other proteins.
SH2 domain binding is dynamically regulated by the activity of tyrosine kinases and phosphatases, which add or remove the phosphotyrosine mark. Additionally, competing SH2 domain-containing proteins can influence which interactions occur, and post-translational modifications of the SH2 domain itself can alter binding. This regulation ensures that signaling is transient and context-dependent.
Key Genes Involved in GO:0042169 SH2 domain binding
The following genes encode proteins that either contain SH2 domains or are known to bind SH2 domains, and they are frequently studied in the context of GO:0042169.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GRB2 | Adaptor protein with an SH2 domain that binds phosphotyrosine motifs on receptors and docking proteins | Target for anticancer peptide analogs and signaling studies |
| SRC | Tyrosine kinase with an SH2 domain that mediates autoinhibition and substrate recognition | Model for SH2 domain regulation and cancer |
| ABL1 | Tyrosine kinase with an SH2 domain involved in leukemia | Drug target and model for SH2 domain binding in cancer |
| PIK3R1 | Regulatory subunit of PI3K containing SH2 domains that bind phosphotyrosines | Cancer and metabolic signaling |
| PLCG1 | Phospholipase C gamma with SH2 domains that mediate membrane recruitment | Signaling downstream of RTKs |
| STAT3 | Transcription factor with an SH2 domain that mediates dimerization upon phosphorylation | Cancer and immune regulation |
| TNS1 | Tensin, a focal adhesion protein with an SH2 domain | Cell migration and cancer |
| PTPN11 | Protein tyrosine phosphatase with SH2 domains that regulate signaling | Developmental disorders and cancer |
| CRK | Adaptor protein with an SH2 domain | Cytoskeletal regulation and cancer |
| NCK1 | Adaptor protein with SH2 domains | Actin dynamics and signaling |
| SHC1 | Adaptor protein with an SH2 domain | Ras-MAPK pathway activation |
| SYK | Kinase with SH2 domains that bind ITAMs | Immune receptor signaling |
| ZAP70 | Kinase with SH2 domains that bind ITAMs | T cell signaling |
| VAV1 | Guanine nucleotide exchange factor with an SH2 domain | Lymphocyte signaling |
| SOCS1 | Suppressor of cytokine signaling with an SH2 domain | Cytokine signaling and immune regulation |
| CISH | Cytokine-inducible SH2-containing protein | Negative regulation of cytokine signaling |
| PTPN6 | SHP-1 phosphatase with SH2 domains | Immune cell signaling |
How Is SH2 domain binding Regulated?
SH2 domain binding is regulated at multiple levels. The phosphorylation state of the ligand is controlled by the opposing activities of tyrosine kinases and phosphatases, which determines whether an SH2 domain can bind. Additionally, the expression levels and subcellular localization of SH2 domain-containing proteins influence interaction networks. Some SH2 domains are autoinhibited by intramolecular interactions that are relieved upon phosphorylation or ligand binding. Furthermore, lipid binding by SH2 domains can modulate their activity and localization. Finally, competitive binding among SH2 domain-containing proteins can shape signaling outcomes.
SH2 domain binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GRB2 | Cancer, Ras signaling | Knockout and point-mutation models to disrupt SH2 binding |
| PTPN11 | Noonan syndrome, leukemia | Knock-in of patient mutations to study SH2 domain binding |
| STAT3 | Cancer, immune dysregulation | Overexpression and knockout to assess SH2-mediated dimerization |
| SOCS1 | Autoimmunity, cytokine signaling | Knockout models to study loss of SH2 domain function |
| TNS1 | Cancer, cell migration | Knockout and tagged knock-in to track SH2 domain localization |
Cancer
Dysregulated SH2 domain binding is a hallmark of many cancers. Mutations that create or destroy phosphotyrosine motifs can lead to constitutive activation of growth-promoting pathways. For example, the GRB2 SH2 domain is a target for anticancer agents because it couples activated receptors to Ras signaling. Small-molecule inhibitors and peptide analogs that block SH2 domain binding are being developed as cancer therapeutics.
Immune and inflammatory diseases
SH2 domain binding is critical for immune receptor signaling, including T cell and B cell activation. Proteins such as ZAP70, SYK, and SOCS family members rely on SH2 domains to propagate or dampen immune signals. Aberrant SH2 domain interactions can contribute to autoimmunity and immunodeficiency.
Developmental disorders
Mutations in genes encoding SH2 domain-containing proteins, such as PTPN11, can cause developmental syndromes like Noonan syndrome, where altered SH2 domain binding affects Ras-MAPK signaling. This highlights the importance of precise SH2 domain interactions in development.
From SH2 domain binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SH2 domain binding affect signaling? | CRISPR knockout of the SH2 domain-containing gene |
| How does a specific phosphotyrosine mutation alter binding? | Point mutation of the ligand tyrosine to phenylalanine |
| Can a disease-associated mutation in an SH2 domain be corrected? | Knock-in of wild-type or mutant SH2 domain |
| Where does an SH2 domain protein localize in cells? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of an SH2 domain protein drive transformation? | Overexpression via CRISPR activation or cDNA |
| Which genes are required for SH2 domain-mediated signaling? | CRISPR library screening with phosphopeptide reporters |
How to Study the SH2 domain binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In-solution binding assay | Binding affinity and specificity | Quantifying SH2 domain-ligand interactions |
| Proximity ligation | Protein-protein interactions in situ | Detecting SH2 domain binding in cells |
| Histochemistry | Spatial distribution of binding | Tissue localization of SH2 domain interactions |
| SH2scan | High-throughput binding selectivity | Mapping SH2 domain preferences for drug discovery |
| X-ray crystallography | 3D structure of complexes | Understanding phosphotyrosine recognition |
| NMR spectroscopy | Conformational changes and binding | Studying dynamics of SH2 domain interactions |
| Surface plasmon resonance | Real-time binding kinetics | Measuring affinity and kinetics |
| CRISPR screening | Functional importance of genes | Identifying regulators of SH2 domain binding |
In-solution binding assays
In-solution SH2 domain binding assays, such as proximity ligation-based methods, allow quantitative measurement of interactions between SH2 domains and their ligands in solution. These assays are useful for determining affinity and specificity and can be adapted for high-throughput screening.
Histochemistry and imaging
SH2 domain histochemistry uses labeled SH2 domains or ligands to visualize binding sites in tissues and cells, providing spatial information about where interactions occur. This method can reveal tissue-specific patterns of SH2 domain binding.
High-throughput mapping
SH2scan and related technologies enable systematic mapping of SH2 domain-ligand binding selectivity, which is valuable for developing inhibitors and degraders. These approaches generate large datasets that can be mined for drug design.
Structural and computational methods
Structural biology techniques such as X-ray crystallography and NMR, combined with computational modeling, provide atomic-level insights into SH2 domain binding. These methods help explain how mutations affect binding and guide the design of selective inhibitors.
How CRISPR Can Be Used to Study GO:0042169 SH2 domain binding
Knockout
CRISPR knockout of genes encoding SH2 domain-containing proteins or their ligands can abolish specific binding interactions, allowing researchers to test the functional consequences in signaling and disease models. For example, knocking out GRB2 can disrupt Ras activation downstream of receptor tyrosine kinases.
Point Mutation
Point mutations can be introduced to alter key residues in the SH2 domain or the phosphotyrosine motif, thereby selectively disrupting binding without affecting protein expression. This is useful for dissecting the contribution of individual interactions.
Knock-in
Knock-in of disease-associated mutations or tagged versions of SH2 domain proteins enables precise modeling of human disease and tracking of protein localization and interactions.
Overexpression
Overexpression of SH2 domain-containing proteins or their ligands can amplify signaling and reveal gain-of-function phenotypes, such as oncogenic transformation.
How EDITGENE Supports SH2 domain binding Research
Researchers studying SH2 domain binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for SH2 domain binding research.
Frequently Asked Questions About SH2 domain binding
What is SH2 domain binding?
SH2 domain binding (GO:0042169) is the molecular function of binding to an SH2 domain, a ~100-amino-acid protein module that typically recognizes phosphotyrosine motifs to mediate signaling interactions.
What genes are involved in SH2 domain binding?
Genes encoding SH2 domain-containing proteins include GRB2, SRC, ABL1, PIK3R1, PLCG1, STAT3, and many others.
What is the function of the SH2 domain?
The SH2 domain functions as a phosphotyrosine-binding module that couples activated tyrosine kinases to downstream signaling proteins.
How is SH2 domain binding regulated?
It is regulated by the phosphorylation state of ligands, by phosphatases and kinases, and by competitive interactions and lipid binding.
What diseases are associated with SH2 domain binding?
Dysregulated SH2 domain binding is associated with cancer, immune disorders, and developmental syndromes such as Noonan syndrome.
What methods are used to study SH2 domain binding?
Common methods include in-solution binding assays, proximity ligation, histochemistry, SH2scan, and structural techniques.
Can SH2 domain binding be targeted by drugs?
Yes, SH2 domain inhibitors and peptide analogs are being developed as anticancer agents.
What is the FLVR motif in SH2 domains?
The FLVR motif is a conserved sequence in SH2 domains that shapes the phosphotyrosine-binding pocket and influences ligand specificity.
Do SH2 domains bind lipids?
Some SH2 domains have been shown to bind lipids, which can modulate their function and localization.
How can CRISPR help study SH2 domain binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of SH2 domain interactions in cells and organisms.
Conclusion
SH2 domain binding (GO:0042169) is a fundamental molecular function that underlies tyrosine kinase signaling specificity and is implicated in numerous diseases. Understanding its mechanisms, regulation, and disease relevance requires a combination of biochemical, structural, and genetic approaches. CRISPR-based models, coupled with advanced binding assays, offer powerful tools to dissect these interactions and to develop targeted therapeutics.
References
- 1. Jaber Chehayeb R et al.. 2020. SH2 Domain Binding: Diverse FLVRs of Partnership.. Front Endocrinol (Lausanne) 11:575220 PMID: 33042028
- 2. Kasembeli MM et al.. 2009. SH2 domain binding to phosphopeptide ligands: potential for drug targeting.. Front Biosci (Landmark Ed) 14(3):1010-22 PMID: 19273114
- 3. Lung FD et al.. 2003. Grb2 SH2 domain-binding peptide analogs as potential anticancer agents.. Biopolymers 71(2):132-40 PMID: 12767115
- 4. Cho W et al.. 2023. Lipid Binding of SH2 Domains.. Methods Mol Biol 2705:239-253 PMID: 37668978
- 5. Lo SH. 2004. Tensin.. Int J Biochem Cell Biol 36(1):31-4 PMID: 14592531
- 6. Buhs S et al.. 2017. SH2 Domain Histochemistry.. Methods Mol Biol 1555:535-545 PMID: 28092054
- 7. Gonzalez Lira LM et al.. 2026. SH2scan: Mapping SH2 Domain-Ligand Binding Selectivity for Inhibitors and Degraders.. J Med Chem 69(4):3932-3940 PMID: 41543922
- 8. Machida K. 2017. In-Solution SH2 Domain Binding Assay Based on Proximity Ligation.. Methods Mol Biol 1555:331-347 PMID: 28092041
